

Neil Boudville

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5212335/publications.pdf>

Version: 2024-02-01

74
papers

2,122
citations

218662

26
h-index

254170

43
g-index

75
all docs

75
docs citations

75
times ranked

2175
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent Peritonitis Associates with Mortality among Patients Treated with Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 1398-1405.	6.1	198
2	Living kidney donation: outcomes, ethics, and uncertainty. Lancet, The, 2015, 385, 2003-2013.	13.7	174
3	International Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysis. Peritoneal Dialysis International, 2020, 40, 244-253.	2.3	159
4	Peritoneal Dialysis-Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). American Journal of Kidney Diseases, 2020, 76, 42-53.	1.9	120
5	Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. American Journal of Kidney Diseases, 2018, 72, 188-197.	1.9	85
6	Duration of Hemodialysis following Peritoneal Dialysis Cessation in Australia and New Zealand: Proposal for a Standardized Definition of Technique Failure. Peritoneal Dialysis International, 2016, 36, 623-630.	2.3	71
7	Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. American Journal of Kidney Diseases, 2018, 71, 814-821.	1.9	66
8	Relapsing and Recurrent Peritoneal Dialysis-Associated Peritonitis: A Multicenter Registry Study. American Journal of Kidney Diseases, 2011, 58, 429-436.	1.9	63
9	Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open, 2018, 8, e018794.	1.9	60
10	Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation, 2019, 34, 2118-2126.	0.7	56
11	Center-Specific Factors Associated with Peritonitis Risk—A Multi-Center Registry Analysis. Peritoneal Dialysis International, 2016, 36, 509-518.	2.3	54
12	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). Journal of the American Society of Nephrology: JASN, 2020, 31, 2653-2666.	6.1	52
13	The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 554-563.	1.9	51
14	An Incident Cohort Study Comparing Survival on Home Hemodialysis and Peritoneal Dialysis (Australia) Tj ETQq0 0 0 rgBT /Overlock 10 Nephrology: CJASN, 2015, 10, 1397-1407.	4.5	50
15	The Association between Peritoneal Dialysis Modality and Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1091-1097.	4.5	49
16	End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases. Nephrology Dialysis Transplantation, 2014, 29, 2277-2286.	0.7	40
17	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. PLoS ONE, 2014, 9, e114897.	2.5	37
18	Oral nutritional supplementation increases caloric and protein intake in peritoneal dialysis patients. American Journal of Kidney Diseases, 2003, 41, 658-663.	1.9	35

#	ARTICLE	IF	CITATIONS
19	The sensitivity and specificity of ultrasound estimation of central venous pressure using the internal jugular vein. <i>Journal of Critical Care</i> , 2012, 27, 315.e7-315.e11.	2.2	34
20	Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1940-1947.	0.7	34
21	Association between causes of peritoneal dialysis technique failure and all-cause mortality. <i>Scientific Reports</i> , 2018, 8, 3980.	3.3	32
22	Comparison of the Diagnostic Accuracy of the <i>MSLN</i> Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum. <i>Disease Markers</i> , 2013, 35, 119-127.	1.3	31
23	Variation in Peritoneal Dialysis-Related Peritonitis Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). <i>American Journal of Kidney Diseases</i> , 2022, 79, 45-55.e1.	1.9	30
24	Peritoneal dialysis practice in Australia and New Zealand: A call to sustain the action. <i>Nephrology</i> , 2016, 21, 535-546.	1.6	29
25	Risk-Factor Profile of Living Kidney Donors. <i>Transplantation</i> , 2016, 100, 1278-1283.	1.0	28
26	Mesothelin and kidney function—Analysis of relationship and implications for mesothelioma screening. <i>Lung Cancer</i> , 2011, 73, 320-324.	2.0	27
27	Use of patient-reported outcome measures and patient-reported experience measures in renal units in Australia and New Zealand: A cross-sectional survey study. <i>Nephrology</i> , 2020, 25, 14-21.	1.6	27
28	The inaccuracy of cystatin C and creatinine-based equations in predicting GFR in orthotopic liver transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2926-2930.	0.7	26
29	Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1556-1563.	4.5	26
30	Physical activity for people with chronic kidney disease: an international survey of nephrologist practice patterns and research priorities. <i>BMJ Open</i> , 2019, 9, e032322.	1.9	26
31	Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2020, 40, 47-56.	2.3	24
32	Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1897-1904.	0.7	20
33	Outcomes of <i>Corynebacterium</i> Peritonitis: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 619-626.	2.3	18
34	An Intervention Design: Supporting Skills Development for Peritoneal Dialysis Trainers. <i>Peritoneal Dialysis International</i> , 2019, 39, 134-141.	2.3	18
35	Perioperative Complications During Living Donor Nephrectomy: Results From a Multicenter Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811985771.	1.1	17
36	Predictors of Transfer to Home Hemodialysis after Peritoneal Dialysis Completion. <i>Peritoneal Dialysis International</i> , 2016, 36, 547-554.	2.3	16

#	ARTICLE	IF	CITATIONS
37	Teaching peritoneal dialysis in Australia: An opportunity for improvement. <i>Nephrology</i> , 2018, 23, 259-263.	1.6	15
38	Increased Inflammatory Response in Association with the Initiation of Hemodialysis Compared with Peritoneal Dialysis in a Prospective Study of End-Stage Kidney Disease Patients. <i>Peritoneal Dialysis International</i> , 2018, 38, 18-23.	2.3	15
39	International peritoneal dialysis training practices and the risk of peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 937-949.	0.7	15
40	Incremental Versus Standard (Full-Dose) Peritoneal Dialysis. <i>Kidney International Reports</i> , 2022, 7, 165-176.	0.8	15
41	2005 Guidelines on targets for solute and fluid removal in adults being treated with chronic peritoneal dialysis: 2019 Update of the literature and revision of recommendations. <i>Peritoneal Dialysis International</i> , 2020, 40, 254-260.	2.3	14
42	Peritoneal dialysis first policy in <sc>Hong Kong</sc> for 35 years: Global impact. <i>Nephrology</i> , 2022, 27, 787-794.	1.6	14
43	End-stage renal disease in living kidney donors. <i>Kidney International</i> , 2014, 86, 20-22.	5.2	13
44	Outcomes of <i>Acinetobacter</i> Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2018, 38, 257-265.	2.3	12
45	Differences in peritoneal dialysis technique survival between patients treated with peritoneal dialysis systems from different companies. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1035-1044.	0.7	12
46	Home Versus Facility Dialysis and Mortality in Australia and New Zealand. <i>American Journal of Kidney Diseases</i> , 2021, 78, 826-836.e1.	1.9	10
47	The Relationship between Body Mass Index and Organism-Specific Peritonitis. <i>Peritoneal Dialysis International</i> , 2018, 38, 206-214.	2.3	9
48	Outcome measures for technique survival reported in peritoneal dialysis: A systematic review. <i>Peritoneal Dialysis International</i> , 2022, 42, 279-287.	2.3	9
49	Effect of FX Dialysers on Systemic Inflammation and Quality of Life in Chronic Haemodialysis Patients. <i>Blood Purification</i> , 2009, 27, 187-193.	1.8	8
50	Direct and indirect costs incurred by Australian living kidney donors. <i>Nephrology</i> , 2018, 23, 1145-1151.	1.6	8
51	Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipients (IMPACT study): a randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1060-1070.	0.7	8
52	Temporal changes and risk factors for death from early withdrawal within 12 months of dialysis initiation—a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 760-769.	0.7	8
53	The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients. , 2019, 29, 377-385.		6
54	Factors Associated with Chronic Kidney Disease Progression in Australian Nephrology Practices. <i>Nephron Clinical Practice</i> , 2012, 121, c36-c41.	2.3	5

#	ARTICLE	IF	CITATIONS
55	The Cost of Organ Donation: Potential Living Kidney Donors' Perspectives: Table 1:. Health and Social Work, 2015, 40, 307-315.	1.0	5
56	“Can I go to Glasgow?” Learnings from patient involvement at the 17th Congress of the International Society for Peritoneal Dialysis (ISPD). Peritoneal Dialysis International, 2020, 40, 12-25.	2.3	5
57	Optimizing Peritoneal Dialysis—Associated Peritonitis Prevention in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 154-161.	4.5	5
58	Icodextrin use for peritoneal dialysis in Australia: A cohort study using Australia and New Zealand Dialysis and Transplant Registry. Peritoneal Dialysis International, 2020, 40, 209-219.	2.3	4
59	Living Kidney Donors™ Financial Expenses and Mental Health. Transplantation, 2021, 105, 1356-1364.	1.0	4
60	Equity and diversity in the nephrology workforce in Australia and New Zealand. Internal Medicine Journal, 2022, 52, 1900-1909.	0.8	4
61	Limited referral to nephrologists from a tertiary geriatric outpatient clinic despite a high prevalence of chronic kidney disease and anaemia. BMC Geriatrics, 2012, 12, 43.	2.7	3
62	Relationship between pulse pressure and inflammation with left ventricular diastolic dysfunction in chronic kidney disease patients. Internal Medicine Journal, 2019, 49, 240-247.	0.8	2
63	KHA—CARI commentary on the KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Nephrology, 2020, 25, 96-98.	1.6	2
64	Socioeconomic disparity, access to care and patient-relevant outcomes after kidney allograft failure. Transplant International, 2021, 34, 2329-2340.	1.6	2
65	Representativeness of the PDOPPS cohort compared to the Australian PD population. Peritoneal Dialysis International, 2022, 42, 403-414.	2.3	2
66	Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial. Clinical Transplantation, 2017, 31, e13043.	1.6	1
67	Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease. Nutrients, 2020, 12, 3376.	4.1	1
68	Impact of Perioperative Complications on Living Kidney Donor Health-Related Quality of Life and Mental Health: Results From a Prospective Cohort Study. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110374.	1.1	1
69	Response to COVID-19 Infection in Hemodialysis Patients: An Australian Perspective. Kidney360, 2020, 1, 829-833.	2.1	1
70	Evaluating data quality in the Australian and New Zealand dialysis and transplant registry using administrative hospital admission datasets and data-linkage. Health Information Management Journal, 0, , 183335832210977.	1.2	1
71	FP468RISK PREDICTORS AND CAUSES OF TECHNIQUE FAILURE WITHIN THE FIRST YEAR OF PERITONEAL DIALYSIS. Nephrology Dialysis Transplantation, 2018, 33, i194-i194.	0.7	0
72	Reply to letter from A Karkar. Peritoneal Dialysis International, 2020, 40, 427-428.	2.3	0

#	ARTICLE	IF	CITATIONS
73	Necrotising, proliferative glomerulonephritis due to monoclonal cryoglobulinaemia. Journal of Nephrology, 2006, 19, 372-4.	2.0	0
74	MO716: A Different Pet Test: The Relationship between Pet Ownership and Peritonitis Risk in the Peritoneal Dialysis Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0